tag:blogger.com,1999:blog-7857054149675424609.post6596660821525637150..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: Regulus Borrows from RNAi Delivery Technologies…5 Years LateDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger5125tag:blogger.com,1999:blog-7857054149675424609.post-70134128565839614752013-10-29T04:57:32.450+00:002013-10-29T04:57:32.450+00:00Regulus was founded by Isis and Alnylam and IP fro...Regulus was founded by Isis and Alnylam and IP from both companies was assigned to Regulus for microRNA purposes. Oh, and by the way, GalNAc was first used for single strand antisense molecules. Mano, who championed it at Alnylam, used it for ASOs when he was at Isis.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-10387808480121015342013-10-25T23:25:00.210+00:002013-10-25T23:25:00.210+00:00Regulus addresed this in their last earnings CC: t...Regulus addresed this in their last earnings CC: they are free to use GalNAcs with no additional payments due to the agreements signed when the company was created, which allow them to use any of Alnylam or Isis's inventions in their miRNA efforts. I believe the parent companies are due royalties on any future drugs.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-22240124003391785792013-10-24T20:19:42.251+00:002013-10-24T20:19:42.251+00:00Alnylam owned 17% of Regulus stock at the end of 2...Alnylam owned 17% of Regulus stock at the end of 2013. That position has been further diluted by a 5+ million share secondary. <br /><br /> <br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /> tettrazininoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-83515890976331375642013-10-24T16:54:25.911+00:002013-10-24T16:54:25.911+00:00tettrazini:
Probably not. Remember, Alnylam stil...tettrazini:<br /><br />Probably not. Remember, Alnylam still holds a monster position in Regulus. The question for me is why has Alnylam not pushed harder for the adoption of their delivery technology by Regulus?Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-78337803395573125692013-10-24T14:51:18.610+00:002013-10-24T14:51:18.610+00:00"It turns out that only now, Regulus finds th..."It turns out that only now, Regulus finds that in order to optimize the product profile for their lead program, anti-miR122 for the pan-genotypic treatment of HCV infection, they really ought to borrow from RNAi delivery, in this case GalNAc-conjugates from Alnylam."<br /><br />Presumably they will have to pay to borrow.tettrazininoreply@blogger.com